Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M61.2Revenue (TTM) $M23.2Net Margin (%)-110.8Altman Z-Score-6.8
Enterprise Value $M61.2EPS (TTM) $-0.8Operating Margin %-89.6Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.9Pre-tax Margin (%)-110.6Higher ROA y-yY
Price/Book2.010-y EBITDA Growth Rate %--Quick Ratio4.1Cash flow > EarningsY
Price/Sales2.35-y EBITDA Growth Rate %--Current Ratio4.8Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-39.7Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-89.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M33.8ROIC % (ttm)-80.0Gross Margin Increase y-yY

Gurus Latest Trades with CRME

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

CRME is held by these investors:

CRME: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Archibald, JenniferSenior Officer 2014-09-08Buy75$7.29-75.45view
Archibald, JenniferSenior Officer 2014-09-05Buy4,100$7.25-75.31view
Archibald, JenniferSenior Officer 2014-09-05Buy100$7.22-75.21view
Archibald, JenniferSenior Officer 2014-09-05Buy3,259$6.7-73.28view
Hunter, William L.Director, Senior Officer 2014-09-05Buy31,000$6.74-73.44view
Hunter, William L.Director, Senior Officer 2014-09-04Buy19,000$6.65-73.08view
RIEDER, ROBERTDirector, Director or Senior Officer of Insider or 2014-06-27Sell2,000$8.65-79.31view
RIEDER, ROBERTDirector, Director or Senior Officer of Insider or 2014-06-26Sell1,500$8.65-79.31view
RIEDER, ROBERTDirector, Director or Senior Officer of Insider or 2014-06-25Sell300$8.63-79.26view
RIEDER, ROBERTDirector, Director or Senior Officer of Insider or 2014-06-25Sell2,000$8.64-79.28view

Press Releases about CRME :

Quarterly/Annual Reports about CRME:

    News about CRME:

    Articles On GuruFocus.com
    Cardiome Announces Agreement with Basilea for Distribution of Zevtera®/Mabelio® (Ceftobiprole) in Sep 12 2017 
    Cardiome to Present at the Rodman & Renshaw 19th Annual Global Investment Conference Sep 05 2017 
    New Data Presented at European Society of Cardiology Congress 2017 Highlights Clinical Benefit of BR Aug 30 2017 
    Cardiome Provides U.S. Regulatory Update For BRINAVESS Aug 21 2017 
    Cardiome To Hold Second Quarter 2017 Financial Results Conference Call On August 8 Aug 01 2017 
    Cardiome Announces Health Canada Approval of AGGRASTAT® High Dose Bolus Regimen Jul 17 2017 
    Cardiome Pharma Corp. Announces Voting Results Jun 23 2017 
    Cardiome Announces Licensing Agreement for XYDALBA™ (Dalbavancin Hydrochloride) to Support Planned Jun 21 2017 
    Cardiome Announces Commercial Launch of BRINAVESS® (Vernakalant Hydrochloride) in Canada Jun 12 2017 
    Cardiome Reports Changes To Senior Management Team May 16 2017 
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat